Connect with us


Validity Launches Everest, the Industry’s Most Comprehensive Email Marketing Success Platform


Today Validity, the most trusted leader in email deliverability, announced the worldwide availability of Everest, an all-new platform for email optimization, analytics, and delivery. The new platform takes advantage of the capabilities of 250ok, Return Path, and BriteVerify, which Validity acquired in the past two years, while adding several critical new features not found in any other solution on the market. With Everest, brands can maximize their email success to engage more customers and accelerate growth.

Since the outset of COVID-19, businesses have turned to digital channels to engage customers, making email more critical than ever. With brands adopting email as their primary communication channel, the competition for engaging consumers at their inboxes has never been higher. At the same time, email marketers face the daunting challenge of keeping up with evolving changes to filtering algorithms that weed out phishing attacks, malware, ransomware, and overall spam. Being heard above the noise seems impossible, but if marketers want to be successful, they need to be far more sophisticated in their ability to design, execute, track, and optimize their email campaigns.

Today will go in the Validity record books as the date we released to the world our newest platform innovation, Everest, said Mark Briggs, chairman and CEO of Validity. This is, by a wide margin, the most comprehensive, insightful, value-add email platform ever offered in our industry. Any business that relies on digital marketing should consider Everest as the key to delivering email success.

Validity built Everest to give marketers everything they need to ensure email success. Everest is a complete email analytics platform powered by Validitys exclusive data feeds, the largest data network in the industry, and widespread integration and support within the email ecosystem. It offers marketers a complete set of tools to prepare, test, optimize, and measure their email campaigns. With fully configurable dashboards, a highly intuitive user interface, and seamless integration with many of the leading email service providers, Everest makes it fast and easy to optimize campaigns. It also features a rich set of reports to track overall performance, with customizable alerts to proactively warn when action is needed.

With Everest, brands will also be able to see how their campaigns perform compared to other global senders as well as against their top competitors. These unique capabilities offer marketers the most complete analysis of their email marketing channels, enabling them to get more email delivered and more customers engaged than ever before.

Plus, Everest provides the most sophisticated email marketers with unique capabilities, available only from Validity, including email certification for avoiding spam filters, View Time Optimization (VTO) for Verizon Media mailboxes, and enterprise-grade managed services.

Everest aids email marketers across their entire marketing workflow, including list hygiene, program strategy, email creative, delivery optimization, and post-delivery analytics, said Scott Ziegler, Validitys senior vice president, product. Bringing together the best pieces of Validity “ which includes 250ok, Return Path, and BriteVerify “ allows us to deliver the most complete email product in market. Seeing the whole picture is key to maximizing ROI from your email program.

Everest offers email marketers the following key benefits:

  • Get more email delivered. Increase inbox placement rates by maintaining a high sender reputation and decreasing the risk of being filtered into spam folders.
  • Get more customers engaged. Give digital marketers the best possible experience by pre-testing your email design, analyzing how customers read your content, and placing brand emails at the top of consumer inboxes.
  • Maintain a healthy marketing database. Keep your contact database clean by verifying email lists and practicing good email hygiene.
  • Gain competitive intelligence. See your email campaigns performance in the context of the broader market, or side-by-side with industry competitors.
  • Stay on top. Incorporate best practices for sending. React quickly to emerging issues. Preserve your campaign performance through the ever-changing email ecosystem of technologies, filtering strategies, and standards.

Everest is available today as an annual subscription and comes in several editions. With varying levels of features and support, brands can choose the plan which best fits their marketing needs. For more information, visit

About Validity

For over 20 years, tens of thousands of organizations throughout the world have relied on Validity solutions to target, contact, engage, and keep customers “ using trustworthy data as a key advantage. Validitys flagship products “ DemandTools, BriteVerify, Return Path, Trust Assessments, 250ok, and GridBuddy “ are all highly rated, #1 solutions for CRM data management, email address verification, inbox deliverability and avoiding the spam folder, and grid CRM applications. These solutions deliver smarter campaigns, more qualified leads, more productive sales, and ultimately faster growth. For more information, visit and connect with us on LinkedIn, Instagram and Twitter.


Charlie Ungashick

[email protected]


OTC Markets Group Welcomes NOVONIX LIMITED to OTCQX


NEW YORK, Sept. 28, 2020 /PRNewswire/ — OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced NOVONIX LIMITED (ASX: NVX; OTCQX: NVNXF), an integrated developer and supplier of high-performance materials, equipment and services for the global lithium-ion battery industry with operations in the USA and Canada and sales in more than 15 countries, has qualified to trade on the OTCQX® Best Market. NOVONIX LIMITED upgraded to OTCQX from the Pink® market.

NOVONIX LIMITED began trading on OTCQX under the symbol "NVNXF" on September 25, 2020. U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on

Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors.  For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws.

"Congratulations to NOVONIX LIMITED on qualifying for the OTCQX Best Market," said Jason Paltrowitz, EVP of Corporate Services at OTC Markets Group. "We are pleased to support innovative and entrepreneurial international companies seeking to build visibility and tradability in the U.S. public markets. Trading on the ASX in Australia and on the OTCQX Market in the U.S. will enable NOVONIX LIMITED to continue to strengthen engagement with a global investor base."

NOVONIX Chairman, Mr Tony Bellas stated: "We are very excited to increase our presence and accessibility in North America by joining OTCQX Best Market at this important time, as our anode manufacturing ramps-up in the USA and our battery technology development activities expand in Canada.  OTCQX is a logical step in response to the increasing interest we have been receiving from North American and other international investors over this past year."

MCAP LLC acted as the company’s OTCQX sponsor.

NOVONIX LIMITED (ASX:NVX, OTCQX: NVNXF) is an integrated developer and supplier of high-performance materials, equipment and services for the global lithium-ion battery industry with operations in the USA and Canada and sales in more than 15 countries.  NOVONIX’s mission is to advance battery technology and materials to accelerate global deployment for a cleaner energy future.

About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market and the Pink® Open Market for 11,000 U.S. and global securities.  Through OTC Link® ATS and OTC Link ECN, we connect a diverse network of broker-dealers that provide liquidity and execution services.  We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.

To learn more about how we create better informed and more efficient markets, visit

OTC Link ATS and OTC Link ECN are SEC regulated ATSs, operated by OTC Link LLC, member FINRA/SIPC.

Subscribe to the OTC Markets RSS Feed

Media Contact:
OTC Markets Group Inc., +1 (212) 896-4428, media[email protected] 

Logo –

Related Links :

Continue Reading


InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures


SHANGHAI, Sept. 28, 2020 /PRNewswire/ — InventisBio, a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, announced the recent completion of a $147 million series D financing which has attracted participation of many top biopharmaceutical and healthcare venture capital funds. This round of investment was led by Hillhouse affiliate GL Ventures, followed by Qiming Venture Partners, Janchor, AIHC Capital, Matrix Partner China, Dyee Capital, E Fund Capital and other investors. The existing shareholders including Lilly Asia Venture, OrbiMed Asia, Pudong Innotek, AdvanTech Capital, and CMB International continued their support. China Renaissance was the exclusive financial advisor of this transaction.

Currently InventisBio has three drug products in the mid- to late-stage clinical development, and one new product just entered global phase I clinical study. Among them, D-0502 is an oral selective estrogen receptor degrader (SERD), which also acts as an estrogen receptor antagonist, with therapeutic potential for the treatment of hormone receptor positive breast cancer. Compared with other oral SERDs under clinical development worldwide, D-0502 has shown promising anti-tumor activity during phase 1 study with excellent bioavailability and tolerable safety profile. In addition, the company has independently developed a third-generation EGFR-T790M tyrosine kinase inhibitor BPI-D0316 and out-licensed China right to Betta Pharma. This product is currently in registration trials of first- and second-line treatment of EGFR-mutated non-small cell lung cancer patients and the trials are progressing smoothly.

Dr. Yaolin Wang, Chairman and CEO of InventisBio, said: "InventisBio is committed to developing first- and best-in-class innovative drugs for cancer and other major diseases. We are grateful and honored to have Hillhouse’s GL Ventures led this series D round and thankful to other top investment funds, as well as the continued support from the existing investors. This investment demonstrated the recognition of our strong pipeline and fully integrated innovative R&D platform by top healthcare investors. It also shows our strategic investors’ confidence in the future success of our company as a key player in the global pharmaceutical market."

Funds raised in this round will be mainly used to support the company’s current products into phase II clinical studies in China and the United States, including D-0502 trials in hormone receptor positive breast cancer and D-0120 trials in gout. This round will also support the company’s global clinical development of other new drugs, enable further expansion of the company’s product pipeline and team.

Michael Yi, co-chief investment officer of Hillhouse Capital and head of biomedicine and medical devices of Hillhouse’s GL Ventures, said: "As a small molecule innovative drug research and development company, InventisBio has an in-depth knowledge of small molecules’ structure activity relationship and integrated understanding and experience in the efficient and successful development of novel molecules. The founding members have more than 20 years of experience in drug discovery and development, thorough understanding of drug’s mechanism of action and selection of lead candidate for development. Since its establishment, InventisBio has balanced innovation and druggability, and has effectively developed multiple assets for diseases with unmet clinical needs. With four drug candidates in various clinical stages and two clinical registration trials ongoing, InventisBio has established its pipeline in two major therapeutic areas of oncology and metabolic diseases. In addition, the company has maintained a leading position in the drug development of similar products in China. We look forward to developing deep collaboration with InventisBio, advancing its drug discovery and clinical development to bring innovative drugs to the market faster to benefit more patients."

About InventisBio

InventisBio is a fast-growing innovative biotech company, co-founded by Dr. Yaolin Wang and other senior scientists. The company’s top management team members have an average of more than 20 years of experience in innovative drug discovery and development, and team management in multinational pharmaceutical companies such as Schering-Plough and Merck, and have contributed to the successful development of blockbuster drugs such as Keytruda and Temodar. The company focuses on the research and development of "best-in-class" and "first-in-class" innovative drugs to address unmet medical needs and to maximize clinical benefits for patients. Under the leadership of senior management team, the company has established a rich pipeline of competitive and proprietary small molecule drugs for the treatment of cancer and metabolic diseases.

About Hillhouse Affiliate GL Ventures

GL Ventures focuses on early-stage innovative companies in healthcare, software services, consumer Internet, emerging consumer brands and services. The GL Ventures team is passionate about partnering with visionary entrepreneurs to create industry leaders that stand the test of time. GL Ventures is the early stage affiliate of Hillhouse Capital, and we have been investing with innovators across the world since 2005. We were one of the earliest investors into some of the largest global companies today, including BeiGene, Zoom, Meituan, JD, Woowa Brothers and many more.

Continue Reading


Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia


FOSTER CITY, Calif. and HANGZHOU, China, Sept. 27, 2020 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced APL-106 (uproleselan) has received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). This approval enables the initiation of a Phase 1 pharmacokinetics (PK) and tolerability study and includes acceptance of a Phase 3 bridging study of APL-106 in combination with chemotherapy in relapsed/refractory acute myeloid leukemia (AML).

“Our team has worked diligently since licensing APL-106 earlier this year, and receiving China IND approval for our Phase 3 bridging study is a major milestone for Apollomics,” said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. “AML is one of the most common leukemias in adults, and there is a strong demand for an effective breakthrough treatment for relapsed/refractory AML. We are pleased that the CDE recognized the need to improve treatment outcomes in this patient population and accepted our Phase 3 bridging study while the Global Phase 3 trial sponsored by GlycoMimetics, our partner, is ongoing. We look forward to initiating our clinical trials in China as we strive to offer a new and effective treatment option for AML patients.”

A comprehensive Phase 3 development program in AML is currently ongoing with uproleselan in the United States by GlycoMimetics. Uproleselan has received Fast Track designation from the U.S. Food and Drug Administration (FDA) as well as Breakthrough Therapy Designation for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan has also been granted Orphan Drug Designation in AML from the FDA and European Union.

About Uproleselan (APL-106)

Discovered and developed by GlycoMimetics, uproleselan (APL-106) is a late clinical stage, first-in-class, targeted inhibitor of E-selectin. Uproleselan (yoo’ pro le’ sel an) is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. Apollomics licensed APL-106 from GlycoMimetics in January 2020. Under the terms of the agreement, Apollomics has the rights and responsibility to develop and commercialize APL-106 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.

About Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow. It is an aggressive disease that causes the bone marrow to produce immature cells that are unable to carry out their normal function and develop into leukemic white blood cells called myeloblasts. In the U.S., there are approximately 20,000 new cases of AML each year and a 5-year survival rate of 28.7%.1 The annual incidence of new cases of AML in China is 21,600, and relapsed/refractory AML has an extremely poor prognosis.2

About Apollomics, Inc.

Apollomics, Inc., incubated by OrbiMed Asia at inception, is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visit

1National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program 2Yang Xiaofeng, Zhang Sufen, Zhang Qingyuan. Practical Therapeutics of Hematological Diseases[M]. Military Medical Science Press, 2008.

Contact Information:

Investor Contact: Wilson W. Cheung Chief Financial Officer (650) 209-4436 [email protected]

China Media Contact:  
Porda Havas International Finance Communications Group
Terence Wong Ivy Lu
General Manager Vice President
(852) 3150 6786 (86) 21 3397 8796
[email protected] [email protected]

U.S. Media Contact: Remy Bernarda Corporate Communications (415) 203-6386 [email protected]

Primary Logo

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News59 mins ago

InventisBio Announces $147 Million Series D Financing Led by Hillhouse Affiliate GL Ventures

SHANGHAI, Sept. 28, 2020 /PRNewswire/ — InventisBio, a clinical stage biotech company dedicated to the research and development of innovative...

gbafNews28 gbafNews28
News59 mins ago

OTC Markets Group Welcomes NOVONIX LIMITED to OTCQX

NEW YORK, Sept. 28, 2020 /PRNewswire/ — OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global...

gbafNews28 gbafNews28
News1 hour ago

Apollomics, Inc. Receives China Investigational New Drug Approval for APL-106 to Initiate a Phase 3 Bridging Study in Acute Myeloid Leukemia

FOSTER CITY, Calif. and HANGZHOU, China, Sept. 27, 2020 — Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery...

gbafNews28 gbafNews28
News4 hours ago

WRTC INVESTIGATION ALERT: Bernstein Liebhard is Investigating Wrap Technologies Limited For Violations of the Securities Laws

Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of...

gbafNews28 gbafNews28
News4 hours ago

GLNG LOSSES ALERT: Bernstein Liebhard is Investigating Golar LNG Limited For Violations of the Securities Laws

Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of...

gbafNews28 gbafNews28
News6 hours ago

PG&E Conducts Public Safety Power Shutoffs in Response to High-Wind Event, Scope of Event Reduced to 65,000

Pacific Gas and Electric Company (PG&E) will continue to de-energize certain electrical lines as part of a Public Safety Power...

gbafNews28 gbafNews28
News8 hours ago

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Gol Linhas Aéreas Inteligentes S.A. Investors of Important November 10 Deadline in Securities Class Action First Filed by the Firm – GOL

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Gol Linhas Areas Inteligentes S.A....

gbafNews28 gbafNews28
News9 hours ago

Raysut Cement dans la réorganisation de l’entreprise : faire appel à de jeunes leaders dans des postes de direction

Le plus grand fabricant de ciment   Oman, Raysut Cement Company (RCC), a annonc aujourd’hui une importante restructuration de l’entreprise,...

gbafNews28 gbafNews28
News9 hours ago

Raysut Cement in Corporate Revamp: Brings on Board Young Leaders in Top Management Roles

Omans largest cement manufacturer, Raysut Cement Company (RCC), today announced a significant corporate revamp bringing on board young leaders from...

gbafNews28 gbafNews28
News13 hours ago

Gingko House Gives Hong Kongers A Reason to #ShareASmile

10,000 “Smiley Meal Boxes” Shared with the Needy   HONG KONG, CHINA – Media OutReach – 27 September 2020 – Over the last 10 days,...